OncoZenge AB (OSTO:ONCOZ) Current Deferred Revenue : kr0.00 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is OncoZenge AB Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

OncoZenge AB's current deferred revenue for the quarter that ended in Sep. 2024 was kr0.00 Mil.

OncoZenge AB Current Deferred Revenue Historical Data

The historical data trend for OncoZenge AB's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoZenge AB Current Deferred Revenue Chart

OncoZenge AB Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Current Deferred Revenue

OncoZenge AB Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Current Deferred Revenue	Get a 7-Day Free Trial											-	-	-	-	-

OncoZenge AB Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of OncoZenge AB's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoZenge AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoZenge AB (OSTO:ONCOZ) » Definitions » Current Deferred Revenue

Comparable Companies

Traded in Other Exchanges

8LY:Germany

Address

Gustavslundsvagen 34, Bromma, SWE, 167 51

Website

https://www.oncozenge.com

OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.

OncoZenge AB Headlines

No Headlines